-
2024-513914-36-00
4
2019-12-17
locally-advanced Anal Carcinoma, Anal cancer stage II and III
-
2024-513039-26-00
4
2019-11-25
non-small cell lung cancer stages IIIA (N2) and selected resectable
st
-
2023-503670-21-00
5
2019-08-28
Patients with newly diagnosed AML and intermediate- or adverse-risk ge
-
2024-515375-35-00
4
2019-08-26
Untreated patients with higher risk MDS and oligoblastic AML eligible
-
2023-507582-25-00
5
2019-08-02
Malignant Extracranial Germ Cell Tumours (MGCT)
-
2023-504932-16-00
5
2019-06-04
Muscle Invasive Bladder Cancer
-
2022-502832-37-00
5
2019-03-01
Acute myeloid leukemia
-
2023-509602-29-00
5
2019-02-11
Patients with Limited Stage Small-Cell Lung Cancer (LS-SCLC)
-
2024-513464-26-00
5
2018-10-18
Multiple Myeloma
-
2024-515783-31-00
5
2018-08-24
Newly Diagnosed Multiple Myeloma
-
2023-503378-19-00
5
2018-08-23
Chronic Plaque Psoriasis
-
2023-509856-32-00
5
2018-07-15
acute lymphoblastic leukemia in children and adolescents
-
2023-506429-13-00
5
2018-05-02
Progressive multiple sclerosis (PMS)
-
2024-513070-21-00
4
2018-02-15
Relapsed Acute Lymphoblastic Leukemia (ALL)
-
2024-515499-12-00
5
2017-10-02
Acute lymphoblastic leukemia
-
2023-505509-18-00
5
2017-07-12
mature aggressive B-cell lymphoma and leukemia in children and adolesc
-
2022-502668-20-00
9
2017-04-11
Solid tumors harboring NTRK fusion
-
2022-501253-37-00
4
2016-02-02
(A) Anal Squamous Cell Carcinoma,
(B) Biliary Adenocarcinoma (gallblad
-
2023-508766-14-00
10
Sickle Cell Disease
-
2024-516240-26-00
5
2024-10-11
Influenza
-
2023-509371-16-00
4
2024-09-25
Idiopathic Pulmonary Fibrosis
-
2023-510249-79-00
4
2024-09-10
Progressive pulmonary fibrosis (PPF)
-
2023-504942-75-01
5
2024-08-22
Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis with or witho
-
2023-505903-22-00
4
2024-07-02
Sepsis associated acute kidney injury